Alle verbonden artikelen

Ovarian Function Suppression: A Deeper Consideration of the Role in Early Breast Cancer and its Potential Impact on Patient Outcomes: A Consensus Statement from an International Expert Panel.

Auteurs : Arboleda B, Bartsch R, de Azambuja E, Hamilton E, Harbeck N, Klemp J, Knauer M, Kuemmel S, Mahtani R, Schwartzberg L, Villarreal-Garza C, Wolff A
Jaar : 2022
Journal : Oncologist
Volume : 27
Pagina's : 722-731

Health-related quality of life in older patients with HER2+ metastatic breast cancer: Comparing pertuzumab plus trastuzumab with or without metronomic chemotherapy in a randomised open-label phase II clinical trial.

Auteurs : Dal Lago L, Uwimana AL, Coens C, Vuylsteke P, Curigliano G, Brouwers B, Jagiello-Gruszfeld A, Altintas S, Tryfonidis K, Poncet C, Bottomley A, Sousa B, Brain E, Wildiers H
Jaar : 2022
Journal : J Geriatr Oncol
Volume : 13
Pagina's : 582-593

Ontogeny and Vulnerabilities of Drug-Tolerant Persisters in HER2+ Breast Cancer.

Auteurs : Chang CA, Jen J, Jiang S, Sayad A, Mer AS, Brown KR, Nixon AML, Dhabaria A, Tang KH, Venet D, Sotiriou C, Deng J, Wong KK, Adams S, Meyn P, Heguy A, Skok JA, Tsirigos A, Ueberheide B, Moffat J, Singh A, Haibe-Kains B, Khodadadi-Jamayran A, Neel BG
Jaar : 2022
Journal : Cancer Discov
Volume : 12
Pagina's : 1022-1045

Interrogating breast cancer heterogeneity using single and pooled circulating tumor cell analysis.

Auteurs : Rothé F, Venet D, Peeters D, Rouas G, Rediti M, Smeets D, Dupont F, Campbell P, Lambrechts D, Dirix L, Sotiriou C, Ignatiadis M
Jaar : 2022
Journal : NPJ Breast Cancer
Volume : 8
Pagina's : 79

Delivering precision oncology to patients with cancer.

Auteurs : Mateo J, Steuten L, Aftimos P, André F, Davies M, Garralda E, Geissler J, Husereau D, Martinez-Lopez I, Normanno N, Reis-Filho JS, Stefani S, Thomas DM, Westphalen CB, Voest E
Jaar : 2022
Journal : Nat Med
Volume : 28
Pagina's : 658-665

Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer.

Auteurs : Geyer CE Jr, Garber JE, Gelber Rd, Yothers G, Taboada M, Ross L, Rastogi P, Cui K, Arahmani A, Aktan G, Armstrong AC, Arnedos M, Balmaña J, Bergh J, Bliss J, Delaloge S, Domchek SM, Eisen A, Elsafy F, Fein LE, Fielding A, Ford JM, Friedman S, Gelmon KA, Gianni L, Gnant M, Hollingsworth SJ, Im SA, Jager A, Jóhannsson ÓÞ, Lakhani SR, Janni W, Linderholm B, Liu TW, Loman N, Korde L, Loibl S, Lucas PC, Marmé F, Martinez de Dueñas E, McConnell R, Phillips KA, Piccart M, Rossi G, Schmutzler R, Senkus E, Shao Z, Sharma P, Singer CF, Stickeler E, Toi M, Traina TA, Viale G, Zoppoli G, Park YH, Yerushalmi R, Yang H, Pang D, Jung KH, Mailliez A, Fan Z, Tennevet I, Zhang J, Nagy T, Sonke GS, Sun Q, Parton M, Colleoni MA, Schmidt M, Brufsky AM, Razaq W, Kaufman B, Cameron D, Campbell C, Tutt ANJ
Jaar : 2022
Journal : Ann Oncol
Volume : 33
Pagina's : 1250-1268

Results of a single-arm pilot study of (32)P microparticles in unresectable locally advanced pancreatic adenocarcinoma with gemcitabine/nab-paclitaxel or FOLFIRINOX chemotherapy.

Auteurs : Ross PJ, Wasan HS, Croagh D, Nikfarjam M, Nguyen N, Aghmesheh M, Nagrial AM, Bartholomeusz D, Hendlisz A, Ajithkumar T, Iwuji C, Wilson NE, Turner DM, James DC, Young E, Harris MT
Jaar : 2022
Journal : ESMO Open
Volume : 7
Pagina's : 100356

Post-Neoadjuvant Treatment Strategies for Patients with Early Breast Cancer.

Auteurs : Agostinetto E, Jacobs F, Debien V, De Caluwé A, Pop CF, Catteau X, Aftimos P, de Azambuja E, Buisseret L
Jaar : 2022
Journal : Cancers (Basel)
Volume : 14

The association between adiposity and anti-proliferative response to neoadjuvant endocrine therapy with letrozole in post-menopausal patients with estrogen receptor positive breast cancer.

Auteurs : Isnaldi E, Richard F, De Schepper M, Leduc S, Maetens M, Geukens T, Van Baelen K, Nguyen HL, Rouas G, Zoppoli G, Cardoso F, Sotiriou C, Larsimont D, Floris G, Biganzoli E, Desmedt C
Jaar : 2022
Journal : NPJ Breast Cancer
Volume : 8
Pagina's : 90

Understanding Molecular Mechanisms of Phenotype Switching and Crosstalk with TME to Reveal New Vulnerabilities of Melanoma.

Auteurs : Najem A, Soumoy L, Sabbah M, Krayem M, Awada A, Journe F, Ghanem GE
Jaar : 2022
Journal : Cells
Volume : 11

Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142.

Auteurs : André T, Lonardi S, Wong KYM, Lenz HJ, Gelsomino F, Aglietta M, Morse MA, van Cutsem E, McDermott R, Hill A, Sawyer MB, Hendlisz A, Neyns B, Abdullaev S, Memaj A, Lei M, Dixon M, Kopetz S, Overman MJ
Jaar : 2022
Journal : Ann Oncol
Volume : 33
Pagina's : 1052-1060

Sacituzumab govitecan as second-line treatment for metastatic triple-negative breast cancer-phase 3 ASCENT study subanalysis.

Auteurs : Carey LA, Loirat D, Punie K, Bardia A, Diéras V, Dalenc F, Diamond JR, Fontaine C, Wang G, Rugo HS, Hurvitz SA, Kalinsky K, OShaughnessy J, Loibl S, Gianni L, Piccart M, Zhu Y, Delaney R, Phan S, Cortés J
Jaar : 2022
Journal : NPJ Breast Cancer
Volume : 8
Pagina's : 72

Tumour infiltrating lymphocytes and ductal carcinoma in situ: The art of thinking counterintuitively.

Auteurs : Salgado R, Fineberg S, De Caluwe A, de Azambuja E
Jaar : 2022
Journal : Eur J Cancer
Volume : 168
Pagina's : 138-140

Circulating DNA in the neoadjuvant setting of early stage colon cancer.

Auteurs : Bregni G, Pretta A, Senti C, Acedo Reina E, Vandeputte C, Trevisi E, Gkolfakis P, Kehagias P, Deleporte A, Van Laethem JL, Vergauwe P, Van den Eynde M, Deboever G, Janssens J, Demolin G, Holbrechts S, Clausse M, De Grez T, Peeters M, DHondt L, Geboes K, Besse-Hammer T, Rothé F, Flamen P, Hendlisz A, Sclafani F
Jaar : 2022
Journal : Acta Oncol
Volume : 61
Pagina's : 1223-1229

What if the future of HER2-positive breast cancer patients was written in miRNAs? An exploratory analysis from NeoALTTO study.

Auteurs : Pizzamiglio S, Cosentino G, Ciniselli CM, De Cecco L, Cataldo A, Plantamura I, Triulzi T, El-Abed S, Wang Y, Bajji M, Nuciforo P, Huober J, Ellard SL, Rimm DL, Gombos A, Daidone MG, Verderio P, Tagliabue E, Di Cosimo S, Iorio MV
Jaar : 2022
Journal : Cancer Med
Volume : 11
Pagina's : 332-339

PREDICT underestimates survival of patients with HER2-positive early-stage breast cancer.

Auteurs : Agostinetto E, Ameye L, Martel S, Aftimos P, Pondé N, Maurer C, El-Abed S, Wang Y, Vicente M, Chumsri S, Bliss J, Kroep J, Colleoni M, Petrelli F, Del Mastro L, Moreno-Aspitia A, Piccart M, Paesmans M, de Azambuja E, Lambertini M
Jaar : 2022
Journal : NPJ Breast Cancer
Volume : 8
Pagina's : 87

Frailty in older adults with cancer (Fabio Gomez, editor) - Part III : Breast cancer in older adults with frailty

Auteurs : Dal Lago L, De Caluwe A, Borghgraef C, Dumont L, Pepersack T
Jaar : 2022
Journal : Book
Volume : part III
Pagina's : 303 - 318

Editorial: Nutrition and the gastrointestinal tract.

Auteurs : Correia MITD, Van Gossum A
Jaar : 2022
Journal : Curr Opin Clin Nutr Metab Care
Volume : 25
Pagina's : 319-320

Trilaciclib prior to gemcitabine plus carboplatin for metastatic triple-negative breast cancer: phase III PRESERVE 2.

Auteurs : Goel S, Tan AR, Rugo HS, Aftimos P, Beelen A, Zhang J, Yi JS, Malik R, OShaughnessy J
Jaar : 2022
Journal : Future Oncol
Volume : 18
Pagina's : 3701-3711

First-in-human phase 1 dose-escalation study of CAN04, a first-in-class interleukin-1 receptor accessory protein (IL1RAP) antibody in patients with solid tumours.

Auteurs : Robbrecht D, Jungels C, Sorensen MM, Spanggaard I, Eskens F, Fretland SØ, Guren TK, Aftimos P, Liberg D, Svedman C, Thorsson L, Steeghs N, Awada A
Jaar : 2022
Journal : Br J Cancer
Volume : 126
Pagina's : 1010-1017